MB-105 in Patients With CD5 Positive T-cell Lymphoma

Phase 2

Recruiting

• Conditions: Lymphoma, T-Cell

• Registration Number: NCT06534060
• Lead Sponsor: March Biosciences Inc

Brief Summary

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon two-stage optimal design.

Detailed Description

The first stage of the Simon two-stage design will enroll approximately 15 evaluable patients. Once the first 6 patients are enrolled, have received one dose of MB-105 at the recommended phase 2 dose (RP2D), and completed at least up to Day 30 of the study, the Independent Data Monitoring Committee (IDMC) will perform a safety analysis. The IDMC will use this analysis to confirm that the RP2D selected for this Phase 2 study is the appropriate dose of MB-105 for further clinical evaluation. The IDMC will either recommend continuing the remainder of the study at the fixed dose of 50 million (5 x 107) Chimeric antigen receptor (CAR) positive cells or recommend other actions, which could include repeating the safety run-in with either a lower or higher dose. The IDMC will not recommend a MB-105 dose greater than those found safe in the phase 1 study. During the safety analysis period after the 6th patient is treated and awaiting data analysis, patients will continue to be screened but not dosed until the IDMC recommendation is made.

If the IDMC confirms the suggested RP2D is the appropriate dose for further clinical evaluation, the study will enroll an additional 9 patients to complete 15 total patients for Stage 1 to obtain a preliminary estimate of response rate per Lugano criteria for peripheral T-cell lymphoma (PTCL) and 2022 Global criteria for cutaneous cases (CTCL). At the end of Stage 1, defined as when the last patient enrolled completes study visits up to Day 56, including efficacy assessment, the IDMC will convene to review all available Stage 1 data and recommend continuation to Stage 2 or closure of enrollment.

Stage 2 will enroll approximately 31 patients, for a total of 46 patients in the study. During Stage 2 the IDMC will convene at least once every 6 months to review safety and efficacy on an ongoing basis. No formal interim analysis is planned after the end of Stage 1, but since this is an open-label study, interim data extracts may be performed to support abstract submissions, presentations, or regulatory discussions. The study will end once the last patient completes at least 12 months of follow-up and end of study (EOS) visit. After EOS, all patients will be asked to participate in a separate long term follow-up (LTFU) study.

Study Timeline

• Study First Submitted: 2024-07-25
• Study First Submitted QC: 2024-07-31
• Study First Posted: 2024-08-02
• Study Start: 2025-02-15
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-06
• Last Update Posted: 2025-05-08
• Primary Completion: 2028-02
• Study Completion: 2029-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 46

Inclusion Criteria

1. Male or female ≥ 18 years of age.

2. Patients with r/r TCL per WHO 2022 criteria.

   1. r/r CTCL that has failed ≥ 2 prior lines of standard of care (SoC) therapy.
   2. r/r PTCL that has failed ≥ 1 prior lines of SoC therapy. Note: patients with CD30+ disease should have received brentuximab vedotin.

3. Has available tumor tissue or willing to undergo biopsy procedure.

4. CD5 positivity confirmed by local laboratory using an approved diagnostic test or LDT.

5. Karnofsky performance score ≥ 70% or higher.

6. Prior CAR T-cell therapy must have occurred > 60 days prior to study enrollment and must have no evidence of CAR persistence.

7. Measurable or detectable disease

   1. PTCL per Lugano criteria
   2. CTCL per Global (ISCL/EORTC/USCCL) criteria.

8. Prior autologous or allogenic hematopoietic stem cell transplant (HSCT) must have occurred more than 60 days prior to study enrollment.

9. Adequate bone marrow function defined as:

   1. Absolute neutrophil count (ANC) ≥ 1500/μL (≥ 1000/μL for patients with prior HSCT or marrow involvement)
   2. Absolute lymphocyte count ≥200 cells/μL
   3. Hemoglobin ≥ 8 g/dL (transfusion permitted)
   4. Platelet count ≥ 75 000/μL (≥50 000/μL for patients with marrow involvement).

10. Organ function as follows:

    1. Cardiac: left ventricular ejection fraction (LVEF) ≥ 50% by Echo or radionuclide scan.

    2. Pulmonary: oxygen saturation ≥ 92% (room air).

    3. Renal: calculated creatinine clearance > 30 mL/min.

    4. Liver:

       • Total bilirubin < 1.5 x ULN (< 2 × upper limit of normal (ULN)) if liver involvement).
       • If no liver involvement and total bilirubin ≥1.5 x ≤ ULN, direct bilirubin < ULN (Gilbert syndrome)
       • Aspartate aminotransferase / alanine aminotransferase < 3 × ULN (5 x ULN if liver involvement).
       • Albumin > 2.5 g/dL.

11. For females of childbearing potential (defined as < 24 months of amenorrhea or not surgically sterile [absence of ovaries and/or uterus]), a negative serum pregnancy test must be documented at screening, and prior to lymphodepletion (conditioning).

12. For females of childbearing potential and males, a highly effective method of contraception together with a barrier method must be used from the start of lymphodepletion (conditioning) and for at least 12 months after the last dose of study agent.

Exclusion Criteria

1. Sezary syndrome. For other tumor types, if there is a suspicion of significant circulating disease at time of leukapheresis, discuss eligibility with medical monitor prior to proceeding.

2. Contraindication to leukapheresis.

3. Prior treatment with any CD5-targeted therapy.

4. Any evidence of the following active viral infections:

   1. HIV infection.
   2. Chronic hepatitis B virus (cHBV) infection with detectable viral load. Patients with cHBV, who are receiving anti-viral prophylaxis, may be enrolled if they are asymptomatic for >5 days prior to signing informed consent (ICF).
   3. Hepatitis C (HCV) infection with detectable viral load. Patients cured of HCV may be enrolled.

5. Presence of any active, uncontrolled systemic bacterial, viral or fungal infection requiring intravenous (IV) anti-infectives, including clinically significant viral infection or uncontrolled viral reactivation of Epstein-Barr virus, Cytomegalovirus, Adenovirus, BK-virus, or Human herpesvirus 6. If treated with anti-infective agents, patients must be asymptomatic for >5 days prior to enrollment.

6. History of other cancer unless disease-free survival ≥ 2 years (cured non-melanoma skin cancer, in situ breast, non-muscle-invasive bladder or in situ cervical cancer are eligible to enter the trial without time limitations).

7. History of hypersensitivity reactions to products containing murine proteins.

8. Active CNS lymphoma.

9. Evidence of acute graft versus host disease (aGVHD) > Grade 2 Mount Sinai Acute GVHD International Consortium (MAGIC) or chronic GVHD > mild (NIH) requiring ongoing systemic steroids and/or multiagent therapy.

10. Patients who have received systemic immunosuppressive therapy for treatment of GVHD within 28 days of leukapheresis.

11. Currently requiring systemic corticosteroid therapy (10 mg/day or less of prednisone or equivalent doses of other systemic steroids are allowed for control of non-exclusionary pre-existing conditions). A 2-week washout is required prior to leukapheresis and prior to lymphodepletion for patients on > 10 mg/day prednisone equivalent.

12. Patients who have received donor lymphocyte infusions within 28 days of MB-105 infusion.

13. Comorbidity that would impair the patient's ability to receive or tolerate MB-105 and/or affect participation in the study:

    1. History of cardio- or cerebrovascular disease including myocardial infarction, unstable angina, or congestive heart failure (NYHA class III-IV) within 6 months or cerebrovascular accident (CVA; stroke) within 12 months prior to informed consent.
    2. History of central nervous system (CNS) disorder(s) such as an uncontrolled seizure disorder, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
    3. Any serious underlying medical or psychiatric condition deemed by the investigator and medical monitor to be exclusionary due to risk to the patient or to protocol compliance.

14. History of autoimmune disorders, including rheumatic diseases and thyroid disorders (though patients with a history of thyroid disease who have undergone successful therapy may be suitable). Exemptions for mild or limited disease may be granted after discussion between the Investigator and sponsor's medical monitor.

15. Participated in active treatment on other interventional research clinical trials < 30 days before enrollment (participation in follow-up permitted).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Incidence of adverse events adverse events	26 months	Incidence, severity, causal relationship of adverse events (AEs) per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Objective response rate (ORR)	26 months	Best objective response rate (ORR) per independent central review as defined by rate of complete response (CR) and PR using the 2014 Lugano criteria and 2022 Global criteria.

Secondary Outcome Measures

Name	Time	Method
Best overall response (BOR) per central review	26 months
Best overall response (BOR) per investigator	26 months
CAR T persistence, anti-CAR T immune responses, and levels of endogenous T-cells over time	26 months
Objective response rate (ORR) per investigator.	26 months
Duration of response (DOR)	26 months	Duration of Response (DOR), defined as time from first observation of response to the time of disease progression or death, whichever comes first (per investigator and by central review).
Overall survival (OS)	26 months	Overall survival (OS), defined as time from administration of MB-105 to death.
Rate of hematopoietic stem cell transplant (HSCT) after MB-105 treatment	26 months
Progression-free survival (PFS)	26 months	Progression-free survival (PFS), defined as time from administration of MB-105 to the time of disease progression or death, whichever comes first (per investigator and by central review).
Incidence of adverse events during the safety monitoring period for acute toxicities	26 months	* All AEs from leukapheresis up to Day 30.; * Related AEs from MB-105 infusion to Day 90 (i.e. excluding only AEs that are clearly an expected event from underlying condition or non-study related treatment).; * SAEs and all-cause mortality from MB-105 infusion to EOS at Month 24.
Rate of successful study product release of MB-105	26 months	Rate of successful study product release of MB-105, defined as the percentage of MB-105 treatments released for clinical use vs the number of leukapheresis harvests performed and/or vs number of batches started.
Rate of successful study product administration	26 months
Time to hematopoietic stem cell transplant (HCST) after MB-105 treatment	26 months

Trial Locations

Locations (12)

University of San Diego (UCSD)-Moores Cancer Center; 🇺🇸 San Diego, California, United States

SCRI - Colorado Blood Cancer Institute (CBCI); 🇺🇸 Denver, Colorado, United States

Moffitt Cancer Center Magnolia Campus; 🇺🇸 Tampa, Florida, United States

University of Iowa; 🇺🇸 Iowa City, Iowa, United States

Massachusetts General Hospital; 🇺🇸 Boston, Massachusetts, United States

University of Nebraska; 🇺🇸 Omaha, Nebraska, United States

Memorial Sloan Kettering Cancer Center; 🇺🇸 New York, New York, United States

University of North Carolina at Chapel Hill; 🇺🇸 Chapel Hill, North Carolina, United States

Cleveland Clinic; 🇺🇸 Cleveland, Ohio, United States

Oregan Health & Science University; 🇺🇸 Portland, Oregon, United States

Baylor College of Medicine; 🇺🇸 Houston, Texas, United States

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States